Sugi Predict

Sugi Predict / Compounds / SCHEMBL2510458

SCHEMBL2510458

SCHEMBL2510458

CON(C)C(=O)c1cncs1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ DYRK1B Q9Y463 1/20 0.41
▸ KMT2A Q03164 4/20 0.40
▸ ICAM1 P05362 1/20 0.40
▸ SELE P16581 1/20 0.40
▸ TRPM8 Q7Z2W7 2/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ MLYCD O95822 1/20 0.34
▸ KIF11 P52732 1/20 0.33
▸ ACLY P53396 1/20 0.33
▸ ACACB O00763 2/20 0.32
▸ PKM P14618 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ RAB9A P51151 3/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2304794 0.81 KMT2A (0.41) KMT2AICAM1SELEPIK3CDKIF11
Hydrochloric Acid SCHEMBL27646829 0.79 KMT2A (0.40) KMT2AICAM1SELEPIK3CDKIF11
SCHEMBL23959147 0.75 KIF11 (0.41) KMT2ATRPM8PIK3CDKIF11ACLY
Hydrochloric Acid SCHEMBL29776090 0.74 KIF11 (0.40) KMT2ATRPM8PIK3CDKIF11ACLY
SCHEMBL1726348 0.73 — —
SCHEMBL23959384 0.73 KIF11 (0.50) KMT2ATRPM8PIK3CDMLYCDKIF11
SCHEMBL10183970 0.72 CLK1 (0.42) CLK1DYRK1ADYRK1BKMT2AICAM1
SCHEMBL30194928 0.72 HRH4 (0.38) KMT2APIK3CDKIF11ACLY
Hydrochloric Acid SCHEMBL27643705 0.72 KMT2A (0.47) KMT2APIK3CDACACBALDH1A1RAB9A
SCHEMBL14594121 0.71 CLK1 (0.54) CLK1DYRK1ADYRK1BKMT2AICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2023-02-09 — — US disclosed
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2023-02-09 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
US-8658641-B2 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections ASTRAZENECA AB (SE) 2014-02-25 — — US disclosed
US-8629270-B2 Tetrahydropyrrolothiazine compounds ELI LILLY AND COMPANY (US) 2014-01-14 — — US disclosed
US-8629270-B2 Tetrahydropyrrolothiazine compounds ELI LILLY AND COMPANY (US) 2014-01-14 — — US disclosed
WO-2013151832-A1 TETRAHYDROPYRROLOTHIAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-10-10 — — WO disclosed
US-20130261111-A1 TETRAHYDROPYRROLOTHIAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-10-03 — — US disclosed
US-20130261111-A1 TETRAHYDROPYRROLOTHIAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-10-03 — — US disclosed
US-20110245224-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2011-10-06 — — US disclosed
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 — — EP disclosed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 — — US disclosed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS HAVCR2, MAVS, FABP1 CLK1 3100/4885DYRK1A 3058/4885DYRK1B 2140/4885
US-20130261111-A1 TETRAHYDROPYRROLOTHIAZINE COMPOUNDS HRH4, HRH3, HRH1 CLK1 3067/4885DYRK1A 2902/4885DYRK1B 2993/4885
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS CLK1 3536/4885DYRK1A 3911/4885DYRK1B 3272/4885
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS CLK1 3536/4885DYRK1A 3911/4885DYRK1B 3272/4885
US-20110245224-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS SDHB, SDHA, RORC CLK1 3308/4885DYRK1A 3099/4885DYRK1B 3266/4885
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 CLK1 3546/4885DYRK1A 4841/4885DYRK1B 4857/4885
US-11814376-B2 Hepatitis b core protein modulators HAVCR2, FABP1, MAVS CLK1 3536/4885DYRK1A 3911/4885DYRK1B 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.